E-drug: Therapeutics Letter 45: Do Single Stereoisomer Drugs Provide Value?
---------------------------------------------
I would like to bring to your attention the June/September 2002 issue
(#45) of the Therapeutics Letter: "Do Single Stereoisomer Drugs Provide
Value?" that is now available on the Therapeutics Initiative web-site at
http://www.ti.ubc.ca/pages/letter45.htm
In this Letter we reviewed the evidence using the example of a couple of
recently marketed stereoisomer drugs: esomeprazole (Nexium) and
levofloxacin (Levaquin). We also reviewed in this Letter some
enantiomeric drugs under development.
We concluded that although the concept that a single enantiomer of a
chiral drug may be preferable to a racemic mixture is intellectually
appealing, in most instances this strategy has not been demonstrated to
confer any clinincal advantage.
I invite you to drop by and have a look at this Letter. Please feel free
to forward this message to any of your friends or colleagues that might
be interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter
and its possible implications in clinical practice.
Best regards,
Ciprian Jauca
Program Coordinator
Therapeutics Initiative - Evidence Based Drug Therapy
University of British Columbia
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
Phone: +1 (604) 822-0700
Fax: +1 (604) 822-0701
Email: jauca@ti.ubc.ca
Web: www.ti.ubc.ca
--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@usa.healthnet.org
Information and archives: http://www.healthnet.org/programs/edrug.html